Bakuchiol Ameliorates Glucocorticoid‐Induced Osteoporosis by Enhancing Osteoblast Differentiation via Targeting FAT4 to Activate YAP1

Read full text
Authors: Hengjun Wang, Tingting Zhou, Yunchao Zhao, Zhengxin Meng, Zhiqiang Sun, Hao Zhou, Huan Liu, Changyu Du, Shuquan Lv, Jianyong Zhao, Zhongyong Zhang, Huantian Cui
Cited by: 1
References: 53

Abstract

Psoralea corylifolia Linn. exhibits osteogenic effects; however, the mechanism by which its active component Bakuchiol (BAK) alleviates glucocorticoid-induced osteoporosis (GIOP) remains unclear. We aim to investigate BAK's therapeutic effects and potential mechanisms in GIOP. We treated GIOP mice with BAK. We evaluated BAK's therapeutic efficacy using micro-CT and histopathological staining. We performed transcriptomic analysis and identified significantly enriched GO pathways. We then used biochemical assays and Western blotting to examine the effects of BAK on osteogenic differentiation-related signaling factors in GIOP mice. We conducted in vitro experiments using osteoblasts. We employed RT-qPCR, Western blot, ALP & ARS staining, immunofluorescence and dual-luciferase reporter assays to assess BAK's influence on signaling pathways related to osteoblast differentiation. We used molecular docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS) to confirm the direct binding interaction between BAK and FAT4. Finally, we silenced Fat4 to validate that BAK exerts its anti-GIOP effects by activating YAP1 through FAT4. BAK treatment significantly enhanced bone quality and strength in GIOP mice, and mitigated femoral pathological damage. BAK upregulated key osteoblast differentiation-related transcription factors and enhanced serum alkaline phosphatase activity. Western blot confirmed that BAK increased protein levels of YAP1 while reducing levels of FAT4 and DCHS1. In vitro, BAK similarly promoted osteoblast differentiation and activated YAP1 expression and Runx2 transcription. Molecular docking, CETSA and DARTS analyses demonstrated that BAK directly binds to FAT4. Silencing Fat4 abolished the pro-osteogenic effects of BAK. BAK likely exerts its therapeutic effects in GIOP by targeting FAT4, activating YAP1 and promoting osteoblast differentiation.

Fields of Study & Subjects

Hippo pathway signaling and YAP/TAZ Bone Metabolism and Diseases Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
Phytotherapy Research
Publisher
Wiley
Volume
40
Issue
8
Pages
5104–5118
Publication date
20 May 2026
Language
EN